Literature DB >> 18519716

Susceptibility testing and molecular classification of Paecilomyces spp.

Maria Victoria Castelli1, Ana Alastruey-Izquierdo, Isabel Cuesta, Araceli Monzon, Emilia Mellado, Juan L Rodriguez-Tudela, Manuel Cuenca-Estrella.   

Abstract

In vitro susceptibility profiles of 58 Paecilomyces clinical isolates are reported. Amphotericin B, itraconazole, and echinocandins showed poor activity against Paecilomyces lilacinus, while the new triazoles were active against it. Paecilomyces variotii exhibited a different susceptibility pattern, being susceptible to most antifungal agents apart from voriconazole and ravuconazole.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18519716      PMCID: PMC2493137          DOI: 10.1128/AAC.00538-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  17 in total

1.  Inoculum standardization for antifungal susceptibility testing of filamentous fungi pathogenic for humans.

Authors:  E Petrikkou; J L Rodríguez-Tudela; M Cuenca-Estrella; A Gómez; A Molleja; E Mellado
Journal:  J Clin Microbiol       Date:  2001-04       Impact factor: 5.948

2.  Comparative evaluation of two different methods of inoculum preparation for antifungal susceptibility testing of filamentous fungi.

Authors:  A Aberkane; M Cuenca-Estrella; A Gomez-Lopez; E Petrikkou; E Mellado; A Monzón; J L Rodriguez-Tudela
Journal:  J Antimicrob Chemother       Date:  2002-11       Impact factor: 5.790

3.  Interlaboratory evaluation of hematocytometer method of inoculum preparation for testing antifungal susceptibilities of filamentous fungi.

Authors:  J L Rodriguez-Tudela; Erja Chryssanthou; Evangelia Petrikkou; Juan Mosquera; David W Denning; Manuel Cuenca-Estrella
Journal:  J Clin Microbiol       Date:  2003-11       Impact factor: 5.948

4.  Voriconazole-resistant disseminated Paecilomyces variotii infection in a neutropenic patient with leukaemia on voriconazole prophylaxis.

Authors:  Georgios Chamilos; Dimitrios P Kontoyiannis
Journal:  J Infect       Date:  2005-11       Impact factor: 6.072

Review 5.  Pulmonary mycetoma caused by an atypical isolate of Paecilomyces species in an immunocompetent individual: case report and literature review of Paecilomyces lung infections.

Authors:  F Gutiérrez; M Masiá; J Ramos; M Elía; E Mellado; M Cuenca-Estrella
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-09       Impact factor: 3.267

6.  Susceptibility patterns and molecular identification of Trichosporon species.

Authors:  Juan L Rodriguez-Tudela; Teresa M Diaz-Guerra; Emilia Mellado; Virginia Cano; Cecilia Tapia; Alexander Perkins; Alicia Gomez-Lopez; Laura Rodero; Manuel Cuenca-Estrella
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

7.  In vitro antifungal activity of a novel lipopeptide antifungal agent, FK463, against various fungal pathogens.

Authors:  K Uchida; Y Nishiyama; N Yokota; H Yamaguchi
Journal:  J Antibiot (Tokyo)       Date:  2000-10       Impact factor: 2.649

Review 8.  Clinical manifestations, treatment and outcome of Paecilomyces lilacinus infections.

Authors:  F J Pastor; J Guarro
Journal:  Clin Microbiol Infect       Date:  2006-10       Impact factor: 8.067

9.  In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates.

Authors:  S Arikan; M Lozano-Chiu; V Paetznick; J H Rex
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

Review 10.  Paecilomyces lilacinus vaginitis in an immuno-competent patient.

Authors:  Jeanne Carey; Ron D'Amico; Deanna A Sutton; Michael G Rinaldi
Journal:  Emerg Infect Dis       Date:  2003-09       Impact factor: 6.883

View more
  25 in total

1.  Cutaneous hyalohyphomycosis caused by Paecilomyces lilacinus successfully treated by oral voriconazole and nystatin packing.

Authors:  Ching-Yu Huang; Pei-Lun Sun; Hsiang-Kuang Tseng
Journal:  Mycopathologia       Date:  2011-03-20       Impact factor: 2.574

2.  A case of indolent endocarditis.

Authors:  Hanane Benbarkat; Karima Addetia; Amir H Salehi; Donald Sheppard; Thao Huynh
Journal:  Can J Infect Dis Med Microbiol       Date:  2012       Impact factor: 2.471

3.  Paecilomyces as a Cause of Lymph Nodes Enlargement in Hodgkin's Lymphoma.

Authors:  Priya Tiwari; Nandini Hazarika; Sunita Ahlawat; Ishita B Sen; Nikhil Shirshi
Journal:  Indian J Pediatr       Date:  2017-06-29       Impact factor: 1.967

4.  Fatal Purpureocillium lilacinum pneumonia in a green tree python.

Authors:  Jean Meyer; Igor Loncaric; Barbara Richter; Joachim Spergser
Journal:  J Vet Diagn Invest       Date:  2017-12-22       Impact factor: 1.279

5.  Purpureocillium lilacinum tattoo-related skin infection in a kidney transplant recipient.

Authors:  Sonya A Trinh; Michael P Angarone
Journal:  Transpl Infect Dis       Date:  2017-04-13       Impact factor: 2.228

6.  Recalcitrant Paecilomyces keratitis.

Authors:  Seetha Lakshmi; Cristina Vanessa Garcia
Journal:  BMJ Case Rep       Date:  2019-04-24

7.  Antifungal activities of SCY-078 (MK-3118) and standard antifungal agents against clinical non-Aspergillus mold isolates.

Authors:  Frédéric Lamoth; Barbara D Alexander
Journal:  Antimicrob Agents Chemother       Date:  2015-04-20       Impact factor: 5.191

8.  Paecilomyces variotii Fungemia in a Patient with Lymphoma Needing Liver Transplant.

Authors:  A P Bellanger; J P Cervoni; J F Faucher; D Weil-Verhoeven; M Ginet; E Deconinck; F Grenouillet
Journal:  Mycopathologia       Date:  2017-04-01       Impact factor: 2.574

9.  Successful treatment of Paecilomyces variotii peritonitis in a liver transplant patient.

Authors:  Meltem Polat; Soner Sertan Kara; Anıl Tapısız; Zeliha Demirtaş; Sinan Sarı; Ayşe Kalkancı; Hasan Tezer; Buket Dalgıç
Journal:  Mycopathologia       Date:  2014-12-23       Impact factor: 2.574

10.  Identification of Paecilomyces variotii in clinical samples and settings.

Authors:  Jos Houbraken; Paul E Verweij; Anthonius J M M Rijs; Andrew M Borman; Robert A Samson
Journal:  J Clin Microbiol       Date:  2010-06-02       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.